OBJECTIVE： To evaluate the effects of DNA repair gene XRCC1 Arg399Gln polymorphism on platinum-based chemotherapy sensitivity and clinical prognosis in patients with ovarian cancer， and to provide evidence-based reference for clinical treatment. METHODS： Retrieved from Embase， Medline， Cochrane Library， VIP， CNKI， CBM and Wanfang database， cohort studies on the relationship of XRCC1 gene Arg399Gln polymorphism with platinum-based combination chemotherapy sensitivity and clinical prognosis in patients with ovarian cancer were collected. Meta-analysis was performed by using Stata 12.0 statistical software after data extraction and quality evaluation with Newcastle-Ottawa scale. RESULTS： A total of 5 studies were included， involving 681 patients with ovarian cancer. According to the detection results of XRCC1 gene Arg399Gln polymorphism， they were divided into wild genotype（Arg/Arg）， mutant heterozygote genotype（Arg/Gln） and mutant homozygote genotype（Gln/Gln）. Results of Meta-analysis showed that there was no statistical significance in chemotherapy sensitivity between Arg/Gln genotype and Arg/Arg genotype[OR＝1.01，95％CI（0.23，4.55），P＝0.977]， Gln/Gln genotype and Arg/Arg genotype[OR＝0.97，95％CI（0.12，7.63），P＝0.969]， Arg/Gln+Gln/Gln genotype and Arg/Arg genotype[OR＝0.95，95％CI（0.19，4.69），P＝0.948]， Arg/Arg+Arg/Gln genotype and Gln/Gln genotype[OR＝1.06，95％CI（0.34，3.32），P＝0.920]， Arg/Arg+Gln/Gln genotype and Arg/Gln genotype[OR＝0.92，95％CI（0.45，1.88），P＝0.829]， Arg and Gln allele[OR＝0.92，95％CI（0.33，2.56），P＝0.877] of patients with ovarian cancer. There was no statistical significance in overall survival time between Arg/Gln genotype and Arg/Arg genotype[HR＝1.09，95％CI（0.79，1.52），P＝0.592]， Gln/Gln genotype and Arg/Arg genotype[HR＝1.16，95％CI（0.35，3.82），P＝0.812] of patients with ovarian cancer. Only one study showed that XRCC1 gene Arg399Gln polymorphism was not associated with progression-free survival time in patients with ovarian cancer（P＞0.05）. CONCLUSIONS： XRCC1 gene Arg399Gln polymorphism is not associated with platinum-based chemotherapy sensitivity and clinical prognosis in patients with ovarian cancer； its polymorphism can not be used as judgment index for chemotherapy sensitivity and clinical prognosis in patients with ovarian cancer.